BioTuesdays

Category - Markets

Matinas Biopharma
Markets

Maxim ups Matinas BioPharma PT to $5 from $2

Maxim Group raised its price target for Matinas BioPharma (NYSE American:MTNB) to $5 from $2 after the American Heart Association meeting over the weekend. The stock closed at $1.11 on Nov. 9. “We are factoring in...

November 12, 2018
AVEO Pharmaceuticals Logo
Markets

HCW ups AVEO Pharma PT to $9 from $6.50

H.C. Wainwright raised its price target for AVEO Pharmaceuticals (NASDAQ:AVEO) to $9 from $6.50 after the company reported positive top line results from its Phase 3 TIVO-3 study, evaluating tivozanib for the treatment...

November 6, 2018
Equillium
Markets

Stifel starts Equillium at buy; PT $22

Stifel initiated coverage of Equillium (NASDAQ:EQ) with a “buy” rating and $22 price target. The stock closed at $16.34 on Nov. 5. “Our bullish thesis centers on the potential for lead asset, EQ001, a first-in-class...

November 6, 2018
Syros-Logo
Markets

Roth ups Syros Pharma to buy; maintains $12 PT

Roth Capital Partners upgraded Syros Pharmaceuticals (NASDAQ:SYRS) to “buy” but maintained its $12 price target, citing recent erosion of the company’s market value. The stock closed at $7.76 on Nov. 2 after trading...

November 5, 2018
Aptevo Therapeutics
Markets

Ladenburg starts Aptevo Therapeutics at buy; PT $14

Ladenburg Thalmann initiated coverage of Aptevo Therapeutics (NASDAQ:APVO) with a “buy” rating and $14 price target. The stock closed at $3.63 on Nov. 2. Aptevo is developing biotherapeutics for oncology and autoimmune...

November 5, 2018
Clovis Oncology Logo
Markets

Leerink cuts Clovis Oncology PT to $22 from $30

Leerink lowered its price target for Clovis Oncology (NASDAQ:CLVS) to $22 from $30 but maintained its “market perform” rating after the company reported third quarter results. The stock closed at $16.61 on Oct. 30...

October 31, 2018
Adial Pharma
Markets

Maxim starts Adial Pharma at buy; PT $5

Maxim Group initiated coverage of Adial Pharmaceuticals (NASDAQ:ADIL) with a “buy” rating and $5 price target. The stock closed at $1.88 on Oct. 29. Adial is developing AD04, an ultra-low-dose ondansetron therapy for...

October 30, 2018
Proteon Therapeutics
Markets

Maxim starts Proteon Therapeutics at buy; PT $5

Maxim Group launched coverage of Proteon Therapeutics (NASDAQ:PRTO) with a “buy” rating and a price target of $5. The stock closed at $1.71 on Oct. 29. The company’s vonapanitase drug candidate is being evaluated in its...

October 30, 2018
Celyad Logo
Markets

WB starts Celyad at OP; fair market value $53

William Blair launched coverage of Celyad S.A. (NASDAQ:CYAD) with an “outperform” rating and a fair value estimate of $53. The stock closed at $23.58 on Oct.29. Celyad’s lead candidate, CYAD-01, is an autologous...

October 30, 2018